Brief: Milestone Pharma Announces Presentation Of Data From Phase 3 RAPID Clinical Trial Of Etripamil Nasal Spray At The American Heart Association Scientific Sessions 2022
25/10/2022 12:47
Oct 25 (Reuters) - Milestone Pharmaceuticals Inc
MIST.O :
* MILESTONE PHARMACEUTICALS ANNOUNCES LATE-BREAKING
PRESENTATION
OF DATA FROM PHASE 3 RAPID CLINICAL TRIAL OF ETRIPAMIL NASAL
SPRAY IN PATIENTS WITH PAROXYSMAL SUPRAVENTRICULAR TACHYCARDIA
AT THE AMERICAN HEART ASSOCIATION SCIENTIFIC SESSIONS 2022
Source text for Eikon: ID:nPn15c2LWa
Further company coverage: MIST.O
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Milestone Pharmaceuticals
See all newsBrief: Milestone Pharmaceuticals Announces First European Study Participant Enrolled In Revera-301 Phase 3 Clinical Trial
Brief: Milestone Pharmaceuticals Says NMPA Approval Triggers $2 Mln Milestone Payment To The Co
Milestone Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary
Canada's Milestone Pharma misses Q2 product revenue expectations
Milestone Pharmaceuticals Inc expected to post a loss of 19 cents a share - Earnings Preview